These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28623485)

  • 1. Is scaffold hopping a reliable indicator for the ability of computational methods to identify structurally diverse active compounds?
    Dimova D; Bajorath J
    J Comput Aided Mol Des; 2017 Jul; 31(7):603-608. PubMed ID: 28623485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic assessment of scaffold hopping versus activity cliff formation across bioactive compound classes following a molecular hierarchy.
    Stumpfe D; Dimova D; Bajorath J
    Bioorg Med Chem; 2015 Jul; 23(13):3183-91. PubMed ID: 25982076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in Scaffold Hopping.
    Hu Y; Stumpfe D; Bajorath J
    J Med Chem; 2017 Feb; 60(4):1238-1246. PubMed ID: 28001064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing Scaffold Diversity of Kinase Inhibitors Using Alternative Scaffold Concepts and Estimating the Scaffold Hopping Potential for Different Kinases.
    Dimova D; Bajorath J
    Molecules; 2017 May; 22(5):. PubMed ID: 28467353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic assessment of scaffold distances in ChEMBL: prioritization of compound data sets for scaffold hopping analysis in virtual screening.
    Li R; Bajorath J
    J Comput Aided Mol Des; 2012 Oct; 26(10):1101-9. PubMed ID: 22972561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scaffold hopping in drug discovery using inductive logic programming.
    Tsunoyama K; Amini A; Sternberg MJ; Muggleton SH
    J Chem Inf Model; 2008 May; 48(5):949-57. PubMed ID: 18457387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target family-directed exploration of scaffolds with different SAR profiles.
    Hu Y; Bajorath J
    J Chem Inf Model; 2011 Dec; 51(12):3138-48. PubMed ID: 22091691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.
    Boström J; Berggren K; Elebring T; Greasley PJ; Wilstermann M
    Bioorg Med Chem; 2007 Jun; 15(12):4077-84. PubMed ID: 17433696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization.
    Langdon SR; Ertl P; Brown N
    Mol Inform; 2010 May; 29(5):366-85. PubMed ID: 27463193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Growth of Bioactive Compounds and Scaffolds over Time: Implications for Lead Discovery and Scaffold Hopping.
    Jasial S; Hu Y; Bajorath J
    J Chem Inf Model; 2016 Feb; 56(2):300-7. PubMed ID: 26838127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scaffold hopping using two-dimensional fingerprints: true potential, black magic, or a hopeless endeavor? Guidelines for virtual screening.
    Vogt M; Stumpfe D; Geppert H; Bajorath J
    J Med Chem; 2010 Aug; 53(15):5707-15. PubMed ID: 20684607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists.
    Lange JH; Kruse CG
    Drug Discov Today; 2005 May; 10(10):693-702. PubMed ID: 15896682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scaffold hopping.
    Böhm HJ; Flohr A; Stahl M
    Drug Discov Today Technol; 2004 Dec; 1(3):217-24. PubMed ID: 24981488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtual screening and scaffold hopping based on GRID molecular interaction fields.
    Ahlström MM; Ridderström M; Luthman K; Zamora I
    J Chem Inf Model; 2005; 45(5):1313-23. PubMed ID: 16180908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic identification of scaffolds representing compounds active against individual targets and single or multiple target families.
    Hu Y; Bajorath J
    J Chem Inf Model; 2013 Feb; 53(2):312-26. PubMed ID: 23339619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of Systematic Molecular Scaffold Enumeration to Enrich Structure-Activity Relationship Information.
    Mok NY; Brown N
    J Chem Inf Model; 2017 Jan; 57(1):27-35. PubMed ID: 27990817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists.
    Han S; Zhang FF; Xie X; Chen JZ
    Eur J Med Chem; 2014 Mar; 74():73-84. PubMed ID: 24445310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analog series-based scaffolds: computational design and exploration of a new type of molecular scaffolds for medicinal chemistry.
    Dimova D; Stumpfe D; Hu Y; Bajorath J
    Future Sci OA; 2016 Dec; 2(4):FSO149. PubMed ID: 28116132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How do 2D fingerprints detect structurally diverse active compounds? Revealing compound subset-specific fingerprint features through systematic selection.
    Heikamp K; Bajorath J
    J Chem Inf Model; 2011 Sep; 51(9):2254-65. PubMed ID: 21793563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scaffold-hopping potential of fragment-based de novo design: the chances and limits of variation.
    Krueger BA; Dietrich A; Baringhaus KH; Schneider G
    Comb Chem High Throughput Screen; 2009 May; 12(4):383-96. PubMed ID: 19442066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.